How Oxford Medical Sciences is fighting Coronavirus
Researchers from across the Medical Sciences Division are working hard to combat the COVID-19 crises. With particular strengths in infectious diseases and international health, we are well placed to contribute to better understanding and effectively controlling the epidemic. We have a long history of responding to crises, in the UK and around the world and are leaders in emergency vaccine development. During the 2014 Ebola outbreak, our scientists performed the world’s first human Ebola vaccine studies, starting them before any other university or company. Our researchers, in collaboration with partners across the globe, are working to develop an effective vaccine and drugs to target this virus, and have already introduced innovative public health measures and collaborative online tools that are being used in hospitals here and abroad.
Coronavirus-related news from across the Medical Sciences Division
21 June 2021
A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.
17 June 2021
Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.
16 June 2021
A new large-scale study shows that a quarter of the UK adult population screens positive for a potential injection phobia.
RECOVERY trial Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients
16 June 2021
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.
10 June 2021
Scientists from the MRC Weatherall Institute of Molecular Medicine at Oxford University have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.
9 June 2021
Created in March 2020 to assist policymakers to make use of existing evidence in mathematical and epidemiological models to inform strategies for minimising the impact of COVID-19, the CoMo Consortium brings together mathematical modellers, epidemiologists, health economists and public health experts from more than 40 countries across Africa, Asia and South and North America.
8 June 2021
The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for patients hospitalised with COVID-19.
8 June 2021
The Pfizer Maternal Covid-19 Vaccine Trial has launched at Oxford University Hospitals NHS Foundation Trust for women between 27-34 weeks pregnant. The Nuffield Department of Women’s & Reproductive Health’s team of doctors, research midwives and nurses are delivering this critical trial to evaluate the safety, tolerability, and immunogenicity of the Pfizer vaccine in pregnant women.
Researchers across the University of Oxford are at the forefront of global efforts to understand COVID-19 and protect our communities.